Evidence map›Paper›PMID 42079030›Full record

ReviewIranian journal of basic medical sciences2026

A review on recent advances in lipid-based drug delivery systems for tuberculosis.

Farah Natasya Zamani, Najihah Mohd Hashim, Rajesh Sreedharan Nair, A'liyatur Rosyidah, Phuoc-Vinh Nguyen, Sonny Kristianto, Intan Nurul Annisha Suhaili, Nur Afifah Othman, Sui Ling Janet Tan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Farah Natasya ZamaniDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Universiti Malaya, 50603 Kuala Lumpur, Malaysia.
Najihah Mohd HashimDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Universiti Malaya, 50603 Kuala Lumpur, Malaysia.
Rajesh Sreedharan NairSchool of Pharmacy, Faculty of Science and Engineering, University of Nottingham Malaysia, Jalan Broga, 43500 Semenyih, Selangor, Malaysia.
A'liyatur RosyidahResearch Center of Vaccine and Drugs, Research Organization for Health, National Research and Innovation Agency (BRIN), Bogor, Indonesia.
Phuoc-Vinh NguyenUniversity of Health Sciences, Vietnam National University, Ho Chi Minh City, Vietnam.
Sonny KristiantoDepartment of Forensic Science, Postgraduate School, Airlangga University, Surabaya, 60286, Indonesia.
Intan Nurul Annisha SuhailiDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Universiti Malaya, 50603 Kuala Lumpur, Malaysia.
Nur Afifah OthmanDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Universiti Malaya, 50603 Kuala Lumpur, Malaysia.
Sui Ling Janet TanDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Universiti Malaya, 50603 Kuala Lumpur, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberculosis (TB) remains a global health challenge, as current therapeutic strategies, albeit effective, require prolonged treatment durations and strict patient adherence. This often results in treatment failure and contributes to the growing issue of antibiotic resistance. To address these challenges, extensive research has focused on innovative drug delivery systems to improve bioavailability, enhance site-specific targeting, and overcome the limitations of conventional TB treatment. In this review, we summarise recent advancements in solid lipid nanoparticles, nanostructured lipid carriers (NLCs), and functionalized lipid nanoparticles for TB treatment. A literature review was conducted focusing on the pathophysiology of TB,

Indexed as

Antitubercular agentsDrug deliveryLipid nanoparticlesLiposomesNanoparticlesTuberculosis

Identifiers

PMID42079030
PMCPMC13135181

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.